Morningstar - Walgreens Boots Alliance Inc (WBA) Walgreens Still in Limbo as It Rolls Out Its Expanded Product Line and Tries to Close Rite Aid

Report

Morningstar

Vishnu Lekraj

EUR 98.48 For Business Accounts Only

Walgreens Still in Limbo as It Rolls Out Its Expanded Product Line and Tries to Close Rite Aid

Walgreens recently reported results that fell in line with our long-term outlook for the retail pharmacy, and we are reiterating our $70 fair value estimate and no-moat rating as the firm continues to try to close the Rite Aid acquisition. The firm has been successful recently in winning prime positions on the preferred pharmacy lists for UnitedHealth, Express Scripts, and other PBMs. Walgreens has been particularly aggressive in becoming the anchor pharmacy for many Medicare Part D plans. In or...

19/04/2017 13 EN

Underlying

Walgreens Boots Alliance Inc

Walgreens Boots Alliance is a holding company. Through its subsidiaries, the company is engaged in retail and wholesale pharmacy. The company's operations are organized into three divisions, which are also its reportable segments: Retail Pharmacy USA; Retail Pharmacy International; and Pharmaceutical Wholesale. The Retail Pharmacy USA division has pharmacy-led health and beauty retail offerings. The Retail Pharmacy International division has pharmacy-led health and beauty retail businesses. The Pharmaceutical Wholesale division, which mainly operates under the Alliance Healthcare brand, supplies medicines, other healthcare products and related services to pharmacies, doctors, health centers and hospitals.

See profile

US9314271084 NASDAQ Stock Market United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Vishnu Lekraj

Other Reports on these Companies

Moody's Investors Service

Moody's Ratings withdraws Walgreens' ratings following acquisition by Sycamore

Moody's Ratings (Moody's) withdrew all of Walgreens Boots Alliance, Inc.'s (Walgreens) ratings including its Ba3 corporate family rating (CFR), Ba3-PD probability of default rating (PDR), and B1 senior unsecured notes ratings and Walgreen Co.'s B1 senior unsecured rating. Previously, the ratings wer...

September 24, 2025 September 24, 2025 1 EN

Moody's Investors Service

Moody's Ratings places Walgreens' ratings under review for downgrade following agreement to be acquired by Sycamore

Moody's Ratings ("Moody's") has today placed the ratings for Walgreens Boots Alliance, Inc. ("WBA") and its subsidiary Walgreen Co. (together combined referred to as "Walgreens") on review for downgrade. Ratings for downgrade include the company's Ba3 corporate family rating ("CFR"), its Ba3-PD pro...

EUR 152.69

March 7, 2025 March 7, 2025 1 EN

Vermilion Research

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

EUR 42.42

February 26, 2025 February 26, 2025 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Walgreens Still in Limbo as It Rolls Out Its Expanded Product Line and Tries to Close Rite Aid

Moody's Ratings withdraws Walgreens' ratings following acquisition by Sycamore

Moody's Ratings places Walgreens' ratings under review for downgrade following agreement to be acquired by Sycamore

Vermilion Booster Shots: Attractive bottom-fishing stocks

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe